AzTrials
AzTrials

Subjective Cognitive Decline (SCD)NCT07463391

Chinese Classics Recitation Training in Subjective Cognitive Decline

A study testing Memory training by Chinese Classics recitation in people with Subjective Cognitive Decline (SCD) and Subjective Cognitive Decline, run by China Medical University Hospital at 1 site in Taiwan.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in… Read more about this study

Who is it for?
Ages 60 years and older
What is being tested?
Memory training by Chinese Classics recitation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteTaiwan
Study dates
1 Aug 2026to 31 Dec 2032
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 60 years old
  • At least two "yes" responses to the following questions are required:
  • Forgetting where things are placed?
  • Unable to recall the names of good friends?
  • Unable to follow and recall conversation?
  • Subjective memory problems?
  • Consider own memory to be worse than others of a similar age?

Who cannot join

  • Objective cognitive impairment defined as ≥ 1.5 standard deviations below standardized cognitive testing (e.g., MMSE)
  • Diagnosis of MCI
  • Clinical Dementia Rating (CDR) ≥ 0.5
  • Diagnosis of major depressive disorder
  • Beck Anxiety Inventory score ≥ 16
  • Other medical or neurological conditions that could explain cognitive decline (e.g., vascular dementia, traumatic brain injury)
  • Claustrophobia
  • Contraindications of MRI (e.g., non-MRI-compatible cardiac pacemaker or devices implanted within the past three months)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sheng-Ta Tsai, M.D., Ph.D. contact

886-928262460

tshengdar@gmail.com

Taiwan1 site, 1 recruiting
  • China Medical University Hospital

    Taichung, 404

    Sheng-Ta Tsai, M.D., Ph.D., 886-928262460, 027056@tool.caaumed.org.tw

    Sheng-Ta Tsai, M.D., Ph.D.

    Recruiting

Other trials in Taiwan

About this study

Official title: The Effect of Memory Training by Chinese Classics Recitation on Individuals With Subjective Cognitive Decline

Subjective cognitive decline (SCD) is considered a preclinical condition associated with an increased risk of dementia and Alzheimer's disease. Effective early behavioral interventions remain limited, and the neurobiological mechanisms underlying cognitive training effects are not fully understood, particularly in culturally specific educational contexts.

This randomized, assessor-blinded, controlled clinical trial will enroll 60 individuals with SCD to evaluate the effects of a six-month structured Chinese Classics recitation training program. Participants will be randomly assigned to either an intervention group or a non-active control group. Assessments will be conducted at baseline, immediately post-intervention, and during annual follow-up.

Multimodal evaluations will include neuropsychological testing, functional magnetic resonance imaging (fMRI), electroencephalography (EEG), blood biomarker profiling, gut microbiota analysis, and fecal metabolomics. The study aims to examine clinical outcomes and explore potential neurobiological and systemic correlates associated with culturally adapted cognitive training.

Being tested
Memory training by Chinese Classics recitation
Keywords
subjective cognitive decline, memory training, Chinese Classics, recitation, randomized controlled trial

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Memory training by Chinese Classics recitationBehavioural

    At least five minutes memory training per day, for six months

Study groups in NCT07463391
Study groupRoleWhat they receive
InterventionExperimentalChinese Classics Recitation for six months
Receives: Behavioral: Memory training by Chinese Classics recitation
non-active controlNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in task-related brain activation measured by functional MRI

    Unit of measure:

    Whole-brain blood-oxygen-level-dependent (BOLD) signal change (%)

    Detail Functional magnetic resonance imaging (fMRI) will be used to evaluate changes in task-related brain activation associated with the intervention. Whole-brain blood-oxygen-level-dependent (BOLD) signals will be analyzed using voxel-wise general linear modeling to identify activation patterns during task performance compared with resting baseline. First-level analyses will generate subject-specific contrast maps reflecting task-related neural activation. Group-level random-effects analyses will then be conducted to compare activation patterns between study groups and across time points. Statistical significance will be determined using a voxel-level threshold corrected for multiple comparisons using the false discovery rate (FDR). Effect sizes extracted from significant brain regions will be used for group-level comparisons.

    Measured: Baseline and 6 months

Secondary outcomes (17)
  1. Resting-state electroencephalogram (EEG) spectral activity

    Unit of Measure µV²/Hz (power spectral density)

    Detail Resting electroencephalogram (EEG) recordings will be acquired using a standard 21-electrode montage positioned according to the International 10-20 system. Electrode impedance will be maintained below 10 kΩ, with a minimum sampling rate of 256 Hz. Recordings will be performed in a quiet, dimly lit environment with participants seated comfortably and instructed to remain awake with their eyes closed.

    EEG preprocessing and analysis will be conducted using MNE-Python implemented in Python. The preprocessing pipeline will include re-referencing, resampling to 250 Hz, and band-pass filtering between 0.1 and 41 Hz. Artifact-free EEG signals will be segmented into non-overlapping 2-second epochs for subsequent spectral analysis. Quantitative EEG measures will be derived from the processed signals to characterize resting-state brain activity.

    Measured: Baseline and 6 months

  2. Global Cognitive Function - MMSE

    Outcome Measure Total score on the Mini-Mental State Examination (MMSE)

    Unit of Measure points

    Detail The MMSE is a widely used cognitive screening instrument assessing orientation, attention, memory, language, and visuospatial ability. Total score ranges from 0-30, with higher scores indicating better cognitive function.

    Measured: Baseline and 6 months

  3. Global Cognitive Function - MoCA

    Outcome Measure Total score on the Montreal Cognitive Assessment (MoCA)

    Unit of Measure points

    Detail The MoCA evaluates multiple cognitive domains including executive function, memory, attention, language, abstraction, and orientation. Total score ranges from 0-30, with higher scores indicating better cognitive performance.

    Measured: Baseline and 6 months

  4. Verbal Episodic Memory - RAVLT

    Outcome Measure Total recall score on the Rey Auditory Verbal Learning Test (RAVLT)

    Unit of Measure points

    Detail The RAVLT assesses verbal learning and episodic memory through repeated recall of word lists across trials. Total recall score reflects the number of correctly recalled words, with higher scores indicating better memory performance.

    Measured: Baseline and 6 months

  5. Executive Function - Stroop Test

    Outcome Measure Interference completion time on the Stroop Color and Word Test

    Unit of Measure seconds

    Detail The Stroop test measures selective attention and cognitive control. The interference condition requires participants to name the ink color of incongruent color words. Lower completion time indicates better executive function.

    Measured: Baseline and 6 months

  6. Working Memory - Digit Span

    Outcome Measure Total span score on the Digit Span Test

    Unit of Measure points

    Detail Digit Span evaluates auditory attention and working memory through forward and backward recall of number sequences. Higher scores indicate better working memory capacity.

    Measured: Baseline and 6 months

  7. Language Function - Boston Naming Test

    Outcome Measure Total score on the Short Form (15 items) of the Boston Naming Test

    Unit of Measure points

    Detail The Boston Naming Test assesses confrontational naming ability. The short form contains 15 items, with total score ranging from 0-15, and higher scores indicating better language function.

    Measured: Baseline and 6 months

  8. Dementia Severity - CDR

    Outcome Measure Global score on the Clinical Dementia Rating (CDR)

    Unit of Measure scale score

    Detail The CDR is a clinician-rated scale evaluating cognitive and functional performance in dementia. Global score ranges from 0 (no impairment) to 3 (severe dementia).

    Measured: Baseline and 6 months

  9. Vascular Cognitive Risk - Hachinski Score

    Outcome Measure Total score on the Hachinski Ischemic Score

    Unit of Measure points

    Detail The Hachinski Ischemic Score differentiates vascular from degenerative causes of cognitive impairment. Scores range from 0-18, with higher scores suggesting greater vascular contribution.

    Measured: Baseline

  10. Depressive Symptoms - GDS

    Outcome Measure Total score on the Geriatric Depression Scale (GDS)

    Unit of Measure points

    Detail The GDS evaluates depressive symptoms in older adults. Higher scores indicate more severe depressive symptoms.

    Measured: Baseline and 6 months

  11. Anxiety Symptoms - BAI

    Outcome Measure Total score on the Beck Anxiety Inventory (BAI)

    Unit of Measure points

    Detail The BAI measures the severity of anxiety symptoms. Total score ranges from 0-63, with higher scores indicating greater anxiety.

    Measured: Baseline and 6 months

  12. Cognitive Reserve - CRI-q

    Outcome Measure Cognitive reserve index score on the Cognitive Reserve Index questionnaire

    Unit of Measure index score

    Detail The CRI-q quantifies lifetime cognitive reserve based on education, occupational complexity, and leisure activities. Higher index scores indicate greater cognitive reserve.

    Measured: Baseline

  13. APOE genotype distribution

    Unit of Measure genotype category

    Detail Genomic DNA will be extracted from peripheral blood samples to determine the genotype of the APOE, a major genetic risk factor associated with cognitive decline and Alzheimer's disease. Participants will be categorized according to APOE genotype (e.g., ε2/ε2, ε2/ε3, ε3/ε3, ε3/ε4, ε4/ε4).

    Measured: Baseline

  14. Circulating inflammatory and stress biomarkers (IL-6, TNF-α, hsCRP, and cortisol)

    Unit of Measure IL-6: pg/mL TNF-α: pg/mL hsCRP: mg/dL Cortisol: µg/dL

    Detail Peripheral venous blood samples will be collected after overnight fasting to quantify circulating inflammatory and stress-related biomarkers, including Interleukin-6, Tumor necrosis factor alpha, High-sensitivity C-reactive protein, and Cortisol. Blood samples will be collected in EDTA anticoagulant tubes and processed within 30 minutes by centrifugation at 2,000 × g for 10 minutes at 4 °C. Plasma will be aliquoted and stored at -80 °C until analysis.

    Cytokine concentration HsCRP concentrations will be measured using high-sensitivity immunoassays to evaluate systemic low-grade inflammation. Plasma cortisol levels will be measured using validated immunoassay methods to assess hypothalamic-pituitary-adrenal (HPA) axis activity and physiological stress responses. Changes in these biomarkers will be analyzed to explore potential inflammatory and neuroendocrine mechanisms associated with the intervention.

    Measured: Baseline and 6 months

  15. Gut microbiota diversity (Shannon index)

    Unit of Measure Shannon diversity index

    Detail Fecal samples will be collected to evaluate changes in gut microbial diversity associated with the intervention. Microbial community composition will be characterized using full-length 16S rRNA gene sequencing, enabling species-level taxonomic identification of intestinal microorganisms. Alpha diversity will be quantified using the Shannon diversity index, which reflects both species richness and evenness within the microbial community. Changes in Shannon diversity between baseline and follow-up will be analyzed to assess intervention-related alterations in gut microbiota diversity.

    Measured: Baseline and 6 months

  16. Gut microbiota taxonomic composition

    Unit of Measure Relative abundance (%)

    Detail Fecal microbiota composition will be analyzed using full-length 16S rRNA gene sequencing to determine the relative abundance of bacterial taxa at different taxonomic levels (e.g., phylum, genus, and species). Differential abundance analyses will be conducted to identify microbial taxa whose relative abundance changes over time or differs between study groups.

    Measured: Baseline and 6 months

  17. Fecal metabolomic profiles related to the gut-brain axis

    Unit of Measure Metabolite concentrations (µmol/g feces or relative abundance)

    Detail Fecal metabolomic profiling will be performed using Liquid chromatography-tandem mass spectrometry to quantify metabolites associated with gut microbiota-host interactions. Metabolites of interest include short-chain fatty acids, bile acids, tryptophan pathway metabolites, neurotransmitter precursors, and inflammation-related metabolites. These analyses will be used to investigate potential metabolic pathways linking gut microbial activity with cognitive and neurophysiological outcomes.

    Measured: Baseline and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Mar 2026
  2. Study start1 Aug 2026
  3. Primary completion31 Jul 2029 (estimated)
  4. Study completion31 Dec 2032 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07463391
Sponsor's protocol ID
CMUH115-REC2-001
Status last verified
Mar 2026
First submitted
1 Mar 2026
Last updated
22 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data will be made available upon reasonable request after publication.

Publications

  • Su TS, Su KP, Hsueh PR, Lai ZL, Chen CM, Lai YC, Chen CS, Nian X, Chang YW, Tsai ST. Memory training through Chinese classics recitation for individuals with subjective cognitive decline: study protocol for a pilot study. Front Aging Neurosci. 2026 Jul 20;18:1830299. doi: 10.3389/fnagi.2026.1830299. eCollection 2026.

    PubMed 42548715

Questions about this trial

What is this clinical trial studying?

A study testing Memory training by Chinese Classics recitation in people with Subjective Cognitive Decline (SCD) and Subjective Cognitive Decline, run by China Medical University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sheng-Ta Tsai, M.D., Ph.D. (886-928262460, tshengdar@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in task-related brain activation measured by functional MRI (time frame: Baseline and 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07463391, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in